
Pubmed-entry ::= {
  pmid 29080044,
  medent {
    em std {
      year 2017,
      month 10,
      day 29,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "Metformin effect on TSH in subclinical hypothyroidism:
 randomized, double-blind, placebo-controlled clinical trial."
      },
      authors {
        names std {
          {
            name ml "Dornelles Severo M",
            affil str "Programa de Pos-Graduacao em Endocrinologia,
 Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Rua Ramiro
 Barcelos, 2400, 2 degrees  andar, Porto Alegre, RS, 90035-003, Brazil."
          },
          {
            name ml "Sturmer Andrade T",
            affil str "Programa de Pos-Graduacao em Endocrinologia,
 Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Rua Ramiro
 Barcelos, 2400, 2 degrees  andar, Porto Alegre, RS, 90035-003, Brazil."
          },
          {
            name ml "Correa Junior V",
            affil str "Programa de Pos-Graduacao em Cardiologia, Universidade
 Federal do Rio Grande do Sul, Faculdade de Medicina, Rua Ramiro Barcelos,
 2400, 2 degrees  andar, Porto Alegre, RS, 90035-003, Brazil."
          },
          {
            name ml "Antonio Naujorks A",
            affil str "Universidade Federal de Santa Maria, Avenida Roraima,
 1000, Santa Maria, RS, 97105-900, Brazil."
          },
          {
            name ml "Gus M",
            affil str "Programa de Pos-Graduacao em Cardiologia, Universidade
 Federal do Rio Grande do Sul, Faculdade de Medicina, Rua Ramiro Barcelos,
 2400, 2 degrees  andar, Porto Alegre, RS, 90035-003, Brazil."
          },
          {
            name ml "Schaan BD",
            affil str "Programa de Pos-Graduacao em Endocrinologia,
 Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Rua Ramiro
 Barcelos, 2400, 2 degrees  andar, Porto Alegre, RS, 90035-003, Brazil.
 bschaan@hcpa.edu.br.; Hospital de Clinicas de Porto Alegre, Rua Ramiro
 Barcelos, 2350, 2 degrees  andar, Porto Alegre, RS, 90035-903, Brazil.
 bschaan@hcpa.edu.br."
          }
        }
      },
      from journal {
        title {
          iso-jta "Endocrine",
          ml-jta "Endocrine",
          issn "1559-0100",
          name "Endocrine"
        },
        imp {
          date std {
            year 2018,
            month 1
          },
          volume "59",
          issue "1",
          pages "66-71",
          language "eng",
          pubstatus ppublish,
          history {
            {
              pubstatus received,
              date std {
                year 2017,
                month 8,
                day 13
              }
            },
            {
              pubstatus accepted,
              date std {
                year 2017,
                month 10,
                day 17
              }
            },
            {
              pubstatus pubmed,
              date std {
                year 2017,
                month 10,
                day 29,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2018,
                month 10,
                day 3,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus other,
              date std {
                year 2017,
                month 10,
                day 29,
                hour 6,
                minute 0
              }
            }
          }
        }
      },
      ids {
        pubmed 29080044,
        doi "10.1007/s12020-017-1462-7",
        pii "10.1007/s12020-017-1462-7",
        other {
          db "ELocationID doi",
          tag str "10.1007/s12020-017-1462-7"
        }
      }
    },
    abstract "INTRODUCTION: Non-randomized trials suggest that metformin may
 reduce TSH levels through unknown mechanisms. OBJECTIVE: To evaluate whether
 metformin can reduce TSH levels in subjects with subclinical hypothyroidism.
 PATIENTS AND METHODS: This is a randomized, double-blind, placebo controlled
 clinical trial with 3 months duration that enrolled 48 individuals, between
 18 and 65 years, with subclinical hypothyroidism. The patients were
 randomized to the use of metformin 850 mg or placebo twice a day for 3
 months. The primary outcome was the absolute decrease in TSH levels.
 Secondary outcomes were changes in the clinical and laboratory assessment, as
 well as in blood pressure assessed by ambulatory blood pressure monitoring.
 RESULTS: After 3 months, 93.75% of participants completed the follow-up. The
 post treatment value of TSH in the metformin and placebo groups were 6.48 +/-
 3.11 and 7.02 +/- 3.28 mIU/L, respectively (p = 0.57). Patients who achieved
 status of euthyroidism in the metformin and placebo groups were 21.7 and
 18.2%, respectively (p = 0.76). There was no significant reduction of TSH
 within the groups [delta for TSH of 0.63 +/- 0.56 (p = 0.28) and 0.54 +/-
 0.60 mIU/L (p = 0.38), in metformin and placebo groups, respectively]. There
 was a small increase in HDL cholesterol (1.62 +/- 0.45 vs. 1.34 +/- 0.39
 mmol/L, p = 0.03) favoring the metformin group. CONCLUSION: Since the sample
 size was small, the study was inconclusive and the results should be
 considered preliminary data of a study that needs to enroll 1626 patients to
 show a 0.5 mIU/L difference in TSH between the groups, with 90% power.",
    mesh {
      {
        term "Adolescent"
      },
      {
        term "Adult"
      },
      {
        term "Aged"
      },
      {
        term "Asymptomatic Diseases"
      },
      {
        term "Blood Pressure",
        qual {
          {
            subh "drug effects"
          }
        }
      },
      {
        term "Cholesterol, HDL",
        qual {
          {
            subh "blood"
          }
        }
      },
      {
        term "Double-Blind Method"
      },
      {
        term "Female"
      },
      {
        term "Humans"
      },
      {
        term "Hypothyroidism",
        qual {
          {
            subh "blood"
          },
          {
            mp TRUE,
            subh "drug therapy"
          }
        }
      },
      {
        term "Insulin Resistance"
      },
      {
        term "Male"
      },
      {
        term "Metformin",
        qual {
          {
            subh "pharmacology"
          },
          {
            mp TRUE,
            subh "therapeutic use"
          }
        }
      },
      {
        term "Middle Aged"
      },
      {
        term "Placebos"
      },
      {
        term "Thyrotropin",
        qual {
          {
            mp TRUE,
            subh "blood"
          }
        }
      },
      {
        term "Young Adult"
      }
    },
    substance {
      {
        type nameonly,
        name "Cholesterol, HDL"
      },
      {
        type nameonly,
        name "Placebos"
      },
      {
        type cas,
        cit "9002-71-5",
        name "Thyrotropin"
      },
      {
        type cas,
        cit "9100L32L2N",
        name "Metformin"
      }
    },
    pmid 29080044,
    pub-type {
      "Journal Article",
      "Randomized Controlled Trial"
    },
    status medline
  }
}


